Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin

REFERENCES

• Benhamou Y, Bochet M, Di MV, et al. Liver fibrosis pro-gression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–1058.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M,Rodriguez-OrengoJF,Rios-BedoyaCF, et al. Effect of hepatitis C virus treatment in fibrosis pro-gression rate (FPR) and time to cirrhosis (TIC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J HepatoL 2007;46:613–619.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibro-sis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21:2209–2216.
   PubMed Web of Science ®Google Scholar
• Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–789.
   PubMed Web of Science ®Google Scholar
• Salmon D, Robain M, Rockstroh JK, Benhamou Y. Therapeutic management of hepatitis and HIV infection in co-infected patients: results of a survey performed before the 2005 Consensus Conference. J Hepatol. 2006;44\(Suppl. 1):S2–S5.
   Google Scholar
• Bruno R, Sacchi P, Puoti M, et al. Natural history of com-pensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 2007;46:297–303.
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mor-tality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat. 2007;14:183–188.
   PubMed Web of Science ®Google Scholar
• Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15:165–172.
   PubMed Web of Science ®Google Scholar
• Smit C, van Den BC, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008;47:221–225.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335–1374.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450.
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839–2848.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginter-feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterfer-on-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
   PubMed Web of Science ®Google Scholar
• Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 KD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatol-ogy. 2004;39:1702–1708.
   PubMed Web of Science ®Google Scholar
• Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004; 350:2265–2271.
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Fried MW, Jeffers Li, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroen-terology. 2006;131:470–477.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46:982–990.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginter-feron alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257–267.
   PubMed Web of Science ®Google Scholar
• Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. J HepatoL 2006;44(1 Suppl):S40–543.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterol-ogy. 2008;135:451–458.
   PubMed Web of Science ®Google Scholar
• Mangia A, Minerva N, Bacca D, et al. Individualized treat-ment duration for hepatitis C genotype 1 patients: a ran-domized controlled trial. Hepatology. 2008;47:43–50.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from pro-longed treatment with the 'accordion' regimen? J HepatoL 2007;47: 580–587.
   PubMed Web of Science ®Google Scholar
• Hopkins S, Lambourne J, Farrell G, et al. Role of individu-alization of hepatitis C virus (HCV) therapy duration in HIV/ HCV-coinfected individuals. HIV Med. 2006;7:248–254.
   PubMed Web of Science ®Google Scholar
• Martin-Carbonero L, Nunez M, Marino A, Alcocer F, et al. Undetectable hepatitis C virus RNA at week 4 as predic-tor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 2008;22:15–21.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried MW, Shiffman ML, et al. Predicting sus-tained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425–433.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Jensen D, Hadziyannis S, Ferenci P. Differentiation of early virological response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (Pegasys) and ribavirin (Copegus) [abstract no. 1308]. Hepatology. 2007;46(4 Suppl. 1):818A.
   Web of Science ®Google Scholar
• Shea DO, Tuite H, Farrell G, et al. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. J Viral Hepat. 2008;15:482–489.
   PubMed Web of Science ®Google Scholar
• Payan C, Pivert A, Morand P, et al. Rapid and early viro-logical response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut. 2007;56:1111–1116.
   PubMed Web of Science ®Google Scholar
• Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009 30;360:1839–1850.
   Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827–1838.
   PubMed Web of Science ®Google Scholar